JP2018526321A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526321A5 JP2018526321A5 JP2017556248A JP2017556248A JP2018526321A5 JP 2018526321 A5 JP2018526321 A5 JP 2018526321A5 JP 2017556248 A JP2017556248 A JP 2017556248A JP 2017556248 A JP2017556248 A JP 2017556248A JP 2018526321 A5 JP2018526321 A5 JP 2018526321A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon
- alkyl
- independently
- composition
- attached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052799 carbon Inorganic materials 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 150000001721 carbon Chemical group 0.000 claims 10
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000002777 nucleoside Substances 0.000 claims 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 206010022000 influenza Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 101710154606 Hemagglutinin Proteins 0.000 claims 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 2
- 101710176177 Protein A56 Proteins 0.000 claims 2
- 229930185560 Pseudouridine Natural products 0.000 claims 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims 2
- 230000033289 adaptive immune response Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims 2
- 239000000185 hemagglutinin Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000005724 cycloalkenylene group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 CC1(C)*(C)(C)C1(*)N Chemical compound CC1(C)*(C)(C)C1(*)N 0.000 description 4
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021096084A JP7506030B2 (ja) | 2015-04-27 | 2021-06-08 | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ |
| JP2024060190A JP2024084804A (ja) | 2015-04-27 | 2024-04-03 | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153143P | 2015-04-27 | 2015-04-27 | |
| US62/153,143 | 2015-04-27 | ||
| PCT/US2016/029572 WO2016176330A1 (en) | 2015-04-27 | 2016-04-27 | Nucleoside-modified rna for inducing an adaptive immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021096084A Division JP7506030B2 (ja) | 2015-04-27 | 2021-06-08 | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018526321A JP2018526321A (ja) | 2018-09-13 |
| JP2018526321A5 true JP2018526321A5 (enExample) | 2019-06-06 |
Family
ID=57199718
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556248A Pending JP2018526321A (ja) | 2015-04-27 | 2016-04-27 | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ |
| JP2021096084A Active JP7506030B2 (ja) | 2015-04-27 | 2021-06-08 | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ |
| JP2024060190A Pending JP2024084804A (ja) | 2015-04-27 | 2024-04-03 | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021096084A Active JP7506030B2 (ja) | 2015-04-27 | 2021-06-08 | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ |
| JP2024060190A Pending JP2024084804A (ja) | 2015-04-27 | 2024-04-03 | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20180303925A1 (enExample) |
| EP (1) | EP3289083A4 (enExample) |
| JP (3) | JP2018526321A (enExample) |
| AU (4) | AU2016253972B2 (enExample) |
| CA (1) | CA2984125A1 (enExample) |
| WO (1) | WO2016176330A1 (enExample) |
Families Citing this family (170)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
| PT3981437T (pt) | 2014-04-23 | 2025-01-15 | Modernatx Inc | Vacinas de ácidos nucleicos |
| HUE060907T2 (hu) * | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| WO2016165825A1 (en) | 2015-04-13 | 2016-10-20 | Curevac Ag | Method for producing rna compositions |
| CA2984125A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| US10221127B2 (en) * | 2015-06-29 | 2019-03-05 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| TW201718638A (zh) | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
| SMT202200178T1 (it) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Composti e composizioni per il rilascio intracellulare di agenti terapeutici |
| US11643441B1 (en) | 2015-10-22 | 2023-05-09 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (VZV) |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| MA45209A (fr) * | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2018081480A1 (en) * | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| PL3386484T3 (pl) * | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| PL3394030T3 (pl) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Związki i kompozycje do wewnątrzkomórkowego dostarczania środków |
| EP3458107B1 (en) | 2016-05-18 | 2024-03-13 | ModernaTX, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| US11001861B2 (en) | 2016-05-18 | 2021-05-11 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
| KR20190086681A (ko) * | 2016-10-26 | 2019-07-23 | 모더나티엑스, 인크. | 면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법 |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| AU2017350488B2 (en) | 2016-10-26 | 2022-06-23 | Acuitas Therapeutics Inc. | Lipid nanoparticle mRNA vaccines |
| WO2018081638A1 (en) * | 2016-10-27 | 2018-05-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US11851389B2 (en) * | 2016-11-08 | 2023-12-26 | Ramot At Tel-Aviv University Ltd. | Cationic lipids for nucleic acid delivery and preparation thereof |
| EP3538146A4 (en) * | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
| US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| AU2017374042C1 (en) * | 2016-12-09 | 2024-07-11 | Acuitas Therapeutics, Inc. | Delivery of target specific nucleases |
| JP7317715B2 (ja) | 2017-01-11 | 2023-07-31 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ジカウイルスに対する免疫応答を誘導するためのヌクレオシド改変ｒｎａ |
| EA201991804A1 (ru) | 2017-02-01 | 2020-02-07 | МОДЕРНАТиЭкс, ИНК. | ИММУНОМОДУЛИРУЮЩИЕ ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ мРНК, КОДИРУЮЩЕЙ ПЕПТИДЫ С АКТИВИРУЮЩЕЙ ОНКОГЕННОЙ МУТАЦИЕЙ |
| UY37621A (es) | 2017-02-28 | 2018-09-28 | Sanofi Sa | Arn terapéutico que codifica citoquinas |
| LT3596041T (lt) * | 2017-03-15 | 2023-01-25 | Modernatx, Inc. | Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys |
| WO2018170245A1 (en) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| AU2018234828A1 (en) | 2017-03-15 | 2019-09-19 | Modernatx, Inc. | Lipid nanoparticle formulation |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| AU2018234814B2 (en) * | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
| US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| US20200038499A1 (en) * | 2017-03-22 | 2020-02-06 | Modernatx, Inc. | Rna bacterial vaccines |
| WO2018188730A1 (en) * | 2017-04-11 | 2018-10-18 | Biontech Rna Pharmaceuticals Gmbh | Rna for treatment of autoimmune diseases |
| US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| WO2018200892A1 (en) * | 2017-04-27 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS |
| CN116693411A (zh) * | 2017-04-28 | 2023-09-05 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2018232355A1 (en) * | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna antibodies |
| US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US12065396B2 (en) | 2017-08-17 | 2024-08-20 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| EP4242223A3 (en) | 2017-08-17 | 2024-03-13 | The Trustees of The University of Pennsylvania | Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof |
| WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| EP3668522B1 (en) * | 2017-08-18 | 2024-09-11 | ModernaTX, Inc. | Efficacious mrna vaccines |
| US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| CA3113436A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US12329857B2 (en) | 2018-09-21 | 2025-06-17 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
| AU2020205717B2 (en) * | 2019-01-11 | 2025-09-11 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| CN118903087A (zh) | 2019-07-26 | 2024-11-08 | 埃斯佩尔维塔治疗股份有限公司 | 可用于预防或治疗疾病的官能化的长链烃一元和二元羧酸 |
| BR112022004759A2 (pt) | 2019-09-19 | 2022-06-21 | Modernatx Inc | Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos |
| WO2021061707A1 (en) | 2019-09-23 | 2021-04-01 | Omega Therapeutics, Inc. | Compositions and methods for modulating apolipoprotein b (apob) gene expression |
| CA3147643A1 (en) | 2019-09-23 | 2021-04-01 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression |
| WO2021076811A1 (en) * | 2019-10-15 | 2021-04-22 | Moderna TX, Inc. | Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease |
| WO2021091272A1 (ko) * | 2019-11-07 | 2021-05-14 | 주식회사 삼양바이오팜 | 면역유도용 고분자 나노입자 조성물 및 그 제조방법 |
| US20230090515A1 (en) | 2019-12-20 | 2023-03-23 | Curevac Ag | Lipid nanoparticles for delivery of nucleic acids |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| WO2021183720A1 (en) | 2020-03-11 | 2021-09-16 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
| CN116583296A (zh) * | 2020-03-31 | 2023-08-11 | 宾夕法尼亚大学理事会 | 使用核苷修饰mrna的通用流感疫苗 |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| AU2021252164A1 (en) | 2020-04-09 | 2022-12-15 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| CN117003658B (zh) * | 2020-04-09 | 2025-10-14 | 苏州艾博生物科技有限公司 | 脂质纳米颗粒组合物 |
| CN113874507A (zh) | 2020-04-09 | 2021-12-31 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
| CA3174215A1 (en) | 2020-04-22 | 2021-10-28 | Ugur Sahin | Coronavirus vaccine |
| WO2022002040A1 (en) | 2020-06-30 | 2022-01-06 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
| EP4178544A4 (en) * | 2020-07-08 | 2024-09-25 | The Trustees of the University of Pennsylvania | NUCLEOSIDE-MODIFIED RNA TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV-2 VIRUS |
| AU2021308681A1 (en) * | 2020-07-16 | 2023-03-09 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| CN114391008B (zh) * | 2020-08-20 | 2024-05-03 | 苏州艾博生物科技有限公司 | 脂质化合物和脂质纳米颗粒组合物 |
| CN114073677B (zh) * | 2020-08-20 | 2023-06-09 | 深圳深信生物科技有限公司 | 一种脂质纳米颗粒 |
| US12419948B2 (en) | 2020-08-31 | 2025-09-23 | The Broad Institute, Inc. | Immunogenic compositions and use thereof |
| IL302064A (en) * | 2020-10-13 | 2023-06-01 | Univ Pennsylvania | Targeting intracorporeal CD4-positive t cells for messenger RNA therapies |
| WO2022081750A1 (en) | 2020-10-14 | 2022-04-21 | George Mason Research Foundation, Inc. | Ionizable lipids and methods of manufacture and use thereof |
| US11771652B2 (en) | 2020-11-06 | 2023-10-03 | Sanofi | Lipid nanoparticles for delivering mRNA vaccines |
| AU2021377746A1 (en) | 2020-11-16 | 2023-06-08 | BioNTech SE | Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same |
| EP4243788A1 (en) | 2020-11-16 | 2023-09-20 | BioNTech SE | Lnp compositions comprising rna and methods for preparing, storing and using the same |
| WO2022218503A1 (en) | 2021-04-12 | 2022-10-20 | BioNTech SE | Lnp compositions comprising rna and methods for preparing, storing and using the same |
| MX2023006056A (es) | 2020-11-25 | 2023-06-06 | Akagera Medicines Inc | Nanoparticulas lipidicas para suministro de acidos nucleicos y metodos de uso de las mismas. |
| EP4025556A4 (en) * | 2020-11-27 | 2023-08-09 | Guangzhou Ribobio Co., Ltd | Lipid compound and the composition thereof |
| WO2022112855A1 (en) * | 2020-11-27 | 2022-06-02 | Guangzhou Ribobio Co., Ltd | Lipid compound and the composition thereof |
| CN113185421B (zh) * | 2020-11-27 | 2022-01-25 | 广州市锐博生物科技有限公司 | 脂质化合物及其组合物 |
| PH12023500013A1 (en) * | 2020-12-04 | 2024-03-11 | Tidal Therapeutics Inc | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof |
| AU2021405281A1 (en) | 2020-12-22 | 2023-07-06 | Glaxosmithkline Biologicals Sa | Rna vaccine against sars-cov-2 variants |
| WO2022152141A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Polymer conjugated lipid compounds and lipid nanoparticle compositions |
| WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
| EP4277601A1 (en) * | 2021-01-15 | 2023-11-22 | Pfizer Inc. | Methods for producing of lipids |
| TW202237073A (zh) | 2021-01-25 | 2022-10-01 | 美商艾斯佩維他治療學公司 | 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途 |
| AU2022256732A1 (en) | 2021-04-12 | 2023-10-19 | Biontech Delivery Technologies Gmbh | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same |
| AU2022281746B2 (en) | 2021-05-24 | 2025-01-16 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
| CA3224056A1 (en) | 2021-06-24 | 2022-12-29 | Peter Seeberger | Continuous flow process for production of cationic lipids |
| EP4183770A1 (en) | 2021-11-22 | 2023-05-24 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Continuous flow process for production of cationic lipids |
| CN117915946A (zh) * | 2021-07-06 | 2024-04-19 | 宾夕法尼亚大学理事会 | 用于丙型肝炎病毒的含P7的核苷修饰mRNA-脂质纳米颗粒谱系疫苗 |
| EP4367242A2 (en) | 2021-07-07 | 2024-05-15 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| CN115703713B (zh) * | 2021-08-13 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| US20250114439A1 (en) * | 2021-08-18 | 2025-04-10 | The Trustees Of The University Of Pennsylvania | mRNA VACCINES AGAINST TICK SALIVARY PROTEINS, AND METHODS OF USING SAME |
| AU2022336209B2 (en) | 2021-09-03 | 2025-10-16 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| MX2024002725A (es) | 2021-09-03 | 2024-03-15 | CureVac SE | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos que comprenden fosfatidilserina. |
| CA3229889A1 (en) | 2021-09-03 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids |
| CA3232386A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
| AR127312A1 (es) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
| CN116064598B (zh) | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
| KR20240090186A (ko) | 2021-10-08 | 2024-06-21 | 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 | 지질 화합물 및 지질 나노 입자 조성물 |
| US20250027108A1 (en) | 2021-10-29 | 2025-01-23 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| KR20240123832A (ko) | 2021-12-16 | 2024-08-14 | 아퀴타스 테라퓨틱스 인크. | 지질 나노입자 제형에 사용하기 위한 지질 |
| AU2022422983A1 (en) | 2021-12-23 | 2024-05-16 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compound and lipid nanoparticle composition |
| MX2024008711A (es) * | 2022-01-19 | 2024-07-22 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipidos y composiciones de nanoparticulas lipidas. |
| CN116554125B (zh) * | 2022-01-27 | 2024-04-05 | 广州立得生物医药科技有限公司 | 一种阳离子脂质类似物、其组合物及应用 |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN116514671A (zh) * | 2022-01-30 | 2023-08-01 | 康希诺生物股份公司 | 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗 |
| WO2023165681A1 (en) | 2022-03-01 | 2023-09-07 | BioNTech SE | Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer |
| CN119072464A (zh) * | 2022-03-25 | 2024-12-03 | 赛欧生物医药股份有限公司 | 新型可电离脂质和脂质纳米颗粒以及其使用方法 |
| WO2023193892A1 (en) | 2022-04-05 | 2023-10-12 | BioNTech SE | Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same |
| JP2025516674A (ja) | 2022-05-13 | 2025-05-30 | ビオンテック エスエー | Ｈｉｖを標的とするｒｎａ組成物 |
| CN119212720A (zh) | 2022-05-25 | 2024-12-27 | 库瑞瓦格欧洲股份公司 | 编码大肠杆菌FimH抗原性多肽的基于核酸的疫苗 |
| IL316504A (en) | 2022-05-25 | 2024-12-01 | BioNTech SE | RNA compositions for the delivery of monkeypox antigens and related methods |
| WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| JP2025518221A (ja) | 2022-05-30 | 2025-06-12 | ビオンテック・ソシエタス・エウロパエア | 核酸の送達のための複合体 |
| CN119604304A (zh) | 2022-06-18 | 2025-03-11 | 葛兰素史克生物有限公司 | 包含非翻译区或编码来自严重急性呼吸道冠状病毒2奥密克戎毒株刺突蛋白的区段的重组rna分子 |
| CN114989182B (zh) * | 2022-06-23 | 2023-06-23 | 尧唐(上海)生物科技有限公司 | 脂质化合物、包含其的组合物及应用 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN119731150A (zh) * | 2022-07-15 | 2025-03-28 | 深圳深信生物科技有限公司 | 一种氨基脂质化合物、其制备方法、组合物和应用 |
| JP2025527245A (ja) | 2022-08-01 | 2025-08-20 | ビオンテック・ソシエタス・エウロパエア | 両親媒性オリゴエチレングリコール（ｏｅｇ）コンジュゲート化合物を含む核酸組成物およびそのような化合物および組成物を使用する方法 |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024094098A1 (zh) * | 2022-11-02 | 2024-05-10 | 益杰立科(上海)生物科技有限公司 | 一种用于递送系统的化合物及其用途 |
| EP4637812A1 (en) | 2022-12-19 | 2025-10-29 | GlaxoSmithKline Biologicals S.A. | Hepatitis b compositions |
| EP4637728A1 (en) | 2022-12-23 | 2025-10-29 | BioNTech Delivery Technologies GmbH | Composition |
| WO2024144267A1 (ko) * | 2022-12-27 | 2024-07-04 | (주)한국바이오셀프 | Hiv-1 mrna를 포함하는 백신 조성물 |
| WO2024141955A1 (en) | 2022-12-28 | 2024-07-04 | BioNTech SE | Rna compositions targeting hiv |
| WO2024163918A1 (en) | 2023-02-02 | 2024-08-08 | University Of Houston System | Mrna vaccine for herpes simplex virus |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024193827A1 (en) | 2023-03-23 | 2024-09-26 | BioNTech SE | Stabilized nucleic acid compositions and methods for preparing, storing and using the same |
| WO2024227433A1 (zh) * | 2023-04-29 | 2024-11-07 | 康希诺(上海)生物研发有限公司 | 一种用于递送核酸药物的脂质纳米颗粒及其制备方法和用途 |
| TW202500750A (zh) | 2023-05-05 | 2025-01-01 | 法商賽諾菲公司 | 用於治療痤瘡的組成物 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| WO2024243438A2 (en) | 2023-05-23 | 2024-11-28 | Omega Therapeutics, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| WO2025003760A1 (en) | 2023-06-28 | 2025-01-02 | Sanofi | Sterol analogs in lipid nanoparticle formulations |
| WO2025027579A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| WO2025030103A1 (en) | 2023-08-03 | 2025-02-06 | The Trustees Of The University Of Pennsylvania | Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof |
| WO2025027576A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| WO2025030134A1 (en) | 2023-08-03 | 2025-02-06 | The Trustees Of The University Of Pennsylvania | Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof |
| WO2025045767A1 (en) | 2023-08-25 | 2025-03-06 | Ethris Gmbh | Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications |
| WO2025072383A1 (en) | 2023-09-25 | 2025-04-03 | The Broad Institute, Inc. | Viral open reading frames, uses thereof, and methods of detecting the same |
| WO2025072921A1 (en) * | 2023-09-29 | 2025-04-03 | Icahn School Of Medicine At Mount Sinai | Chimeric influenza virus hemagglutinin mrna-based vaccines and uses thereof |
| WO2025082397A1 (zh) * | 2023-10-19 | 2025-04-24 | 仁景(苏州)生物科技有限公司 | 用于递送的脂质化合物及脂质纳米颗粒 |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025106806A1 (en) | 2023-11-17 | 2025-05-22 | Acuitas Therapeutics, Inc. | Pegylated lipids |
| WO2025128696A1 (en) | 2023-12-12 | 2025-06-19 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025124711A1 (en) | 2023-12-13 | 2025-06-19 | BioNTech SE | Glycolipid compositions |
| WO2025132122A1 (en) | 2023-12-13 | 2025-06-26 | Berlin Institute Of Health | Methods of delivering therapeutics using lipid nanoparticles |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025129158A1 (en) | 2023-12-15 | 2025-06-19 | The Broad Institute, Inc. | Engineered arc delivery vesicles and uses thereof |
| WO2025141521A1 (en) | 2023-12-29 | 2025-07-03 | Sanofi | Lipids having dendritic moieties |
| CN119874554B (zh) * | 2024-02-02 | 2025-08-19 | 仁景(苏州)生物科技有限公司 | 用于递送的脂质化合物和脂质纳米颗粒 |
| WO2025174858A1 (en) | 2024-02-15 | 2025-08-21 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025184508A1 (en) | 2024-03-01 | 2025-09-04 | Acuitas Therapeutics, Inc. | Materials and methods for encapsulating therapeutics in lipid nanoparticles |
| WO2025186725A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Improved lnp formulations and uses thereof |
| WO2025217264A1 (en) | 2024-04-10 | 2025-10-16 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025229572A1 (en) | 2024-05-01 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines |
| WO2025240833A1 (en) | 2024-05-17 | 2025-11-20 | Acuitas Therapeutics, Inc. | Galnac lipid compounds for use in lipid nanoparticles |
| WO2025255393A1 (en) | 2024-06-06 | 2025-12-11 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus antigen binding agents for mitigation of herpes simplex virus associated disease |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2856420A (en) | 1955-12-15 | 1958-10-14 | Minnesota Mining & Mfg | Perfluoro- and perfluorochlorocarboxylic acid esters of amino alcohols |
| US3340299A (en) | 1964-03-27 | 1967-09-05 | Air Reduction | Tetrasubstituted ethylene diamines |
| JPS5122416B2 (enExample) | 1972-11-11 | 1976-07-09 | ||
| JPS5331118U (enExample) | 1976-08-24 | 1978-03-17 | ||
| US4883751A (en) | 1986-05-28 | 1989-11-28 | New York University | Specific immunoassay for heparin |
| JPH11510489A (ja) | 1995-07-21 | 1999-09-14 | ジンタ・インコーポレイテッド | 新規アミド基本カチオン性脂質 |
| DE19605175A1 (de) | 1996-02-13 | 1997-08-14 | Sourovoi Andrej Dr | Lipidverbindungen und deren Verwendung |
| CA2217550A1 (en) | 1996-10-22 | 1998-04-22 | F. Hoffmann-La Roche Ag | Cationic lipids for gene therapy |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| US6333433B1 (en) | 1998-11-09 | 2001-12-25 | Council Of Scientific Industrial Research | Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkl group for intracellular delivery of biologically active molecules |
| US6656498B1 (en) | 1998-11-25 | 2003-12-02 | Vanderbilt University | Cationic liposomes for gene transfer |
| US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| EP1619254B1 (en) | 1999-09-09 | 2010-12-22 | CureVac GmbH | Transfer of mRNA using polycationic compounds |
| GB9930533D0 (en) | 1999-12-23 | 2000-02-16 | Mitsubishi Tokyo Pharm Inc | Nucleic acid delivery |
| JP2001338416A (ja) | 2000-05-25 | 2001-12-07 | Sony Corp | ディスク状磁気記録媒体 |
| US20040142474A1 (en) | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
| DE50214379D1 (de) | 2001-06-05 | 2010-05-27 | Curevac Gmbh | Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| JP4111856B2 (ja) | 2002-04-12 | 2008-07-02 | 昭和電工株式会社 | 安定化されたアスコルビン酸誘導体 |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| AU2004255456B2 (en) | 2003-07-11 | 2010-06-24 | Intercell Ag | HCV vaccines |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| JP5777846B2 (ja) * | 2005-06-15 | 2015-09-09 | マサチューセッツ インスティテュート オブ テクノロジー | アミン含有脂質およびその使用 |
| HUE043492T2 (hu) | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
| DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| MX2009008706A (es) | 2007-02-21 | 2009-09-14 | Univ Massachusetts | Anticuerpos humanos contra el virus de la hepatitis c (hcv) y usos de los mismos. |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| US20090082803A1 (en) | 2007-09-26 | 2009-03-26 | Aga Medical Corporation | Braided vascular devices having no end clamps |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| KR101483715B1 (ko) | 2008-01-31 | 2015-01-19 | 큐어백 게엠바하 | 면역증강제／애주번트인 화학식（ＮｕＧｌＸｍＧｎＮｖ）ａ를 포함하는 핵산 및 이의 유도체 |
| FR2932388B1 (fr) | 2008-06-17 | 2013-03-29 | Univ Rabelais Francois | Nouvelles proteines de fusion et leur application pour la preparation de vaccins contre l'hepatite c |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| EP2743265B1 (en) | 2008-10-09 | 2017-03-15 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| JP2012509366A (ja) | 2008-11-17 | 2012-04-19 | エンゾン ファーマシューティカルズ，インコーポレーテッド | 核酸送達系のための放出可能ポリマー脂質 |
| WO2011005799A2 (en) * | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| CN107028886A (zh) | 2009-11-04 | 2017-08-11 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
| US9408914B2 (en) | 2010-04-28 | 2016-08-09 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
| WO2011143230A1 (en) | 2010-05-10 | 2011-11-17 | Alnylam Pharmaceuticals | Methods and compositions for delivery of active agents |
| JP2013531634A (ja) * | 2010-05-24 | 2013-08-08 | メルク・シャープ・エンド・ドーム・コーポレイション | オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質 |
| MX341332B (es) | 2010-06-03 | 2016-08-16 | Alnylam Pharmaceuticals Inc | Lipidos biodegradables para la administracion de agentes activos. |
| WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| CN113214102A (zh) | 2010-11-15 | 2021-08-06 | 生命技术公司 | 含胺的转染试剂及其制备和使用方法 |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| AU2012315965A1 (en) | 2011-09-27 | 2014-04-03 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted PEGylated lipids |
| EP2768958B1 (en) | 2011-10-18 | 2019-08-14 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
| JP2013095755A (ja) | 2011-11-02 | 2013-05-20 | Kyowa Hakko Kirin Co Ltd | カチオン性脂質 |
| US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| EP4144378A1 (en) | 2011-12-16 | 2023-03-08 | ModernaTX, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| SI2817287T1 (sl) | 2012-02-24 | 2019-02-28 | Arbutus Biopharma Corporation | Trialkilni kationski lipidi in postopki za njihovo uporabo |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| MX357803B (es) | 2012-03-27 | 2018-07-24 | Curevac Ag | Moléculas de ácido nucleico artificiales. |
| RU2660565C2 (ru) | 2012-03-27 | 2018-07-06 | Кьюрвак Аг | Молекулы искусственной нуклеиновой кислоты, содержащие 5'utr гена top |
| RU2658490C2 (ru) | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| US20150306249A1 (en) | 2012-05-25 | 2015-10-29 | Curevac Gmbh | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
| EP2882706A1 (en) | 2012-08-13 | 2015-06-17 | Massachusetts Institute of Technology | Amine-containing lipidoids and uses thereof |
| JP6456305B2 (ja) | 2013-02-22 | 2019-01-23 | キュアバック アーゲー | ワクチン接種とｐｄ−１経路の阻害との組み合わせ |
| WO2014160284A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of stroke |
| WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
| RU2712743C2 (ru) | 2013-08-21 | 2020-01-30 | Куревак Аг | Вакцина против бешенства |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| SG11201510746WA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Respiratory syncytial virus (rsv) vaccine |
| KR20160043103A (ko) | 2013-08-21 | 2016-04-20 | 큐어백 아게 | 전립선암 치료를 위한 조성물 및 백신 |
| EA037217B1 (ru) | 2013-08-21 | 2021-02-20 | Куревак Аг | Композиция и вакцина для лечения рака легких |
| SG10201801428RA (en) | 2013-08-21 | 2018-03-28 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| CA2925021C (en) | 2013-11-01 | 2025-05-06 | Curevac Ag | MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| SG10201903381TA (en) | 2013-12-30 | 2019-05-30 | Curevac Ag | Artificial nucleic acid molecules |
| EP3556353A3 (en) | 2014-02-25 | 2020-03-18 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| EP3129050A2 (en) | 2014-04-01 | 2017-02-15 | CureVac AG | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| PT3981437T (pt) | 2014-04-23 | 2025-01-15 | Modernatx Inc | Vacinas de ácidos nucleicos |
| EP3146221B1 (en) | 2014-05-22 | 2019-05-08 | Flowserve S.r.l. | Guide element for a valve actuator and actuator provided with said guide element |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| JP6339884B2 (ja) | 2014-07-17 | 2018-06-06 | 富士フイルム株式会社 | イミダゾール化合物およびそれを含有するリポソーム |
| US11149278B2 (en) | 2014-12-12 | 2021-10-19 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
| CA2962849A1 (en) | 2014-12-16 | 2016-06-23 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
| EP3240558A1 (en) | 2014-12-30 | 2017-11-08 | CureVac AG | Artificial nucleic acid molecules |
| WO2016165825A1 (en) | 2015-04-13 | 2016-10-20 | Curevac Ag | Method for producing rna compositions |
| CA2984125A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| ES2875589T3 (es) | 2015-05-15 | 2021-11-10 | Curevac Ag | Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm |
| EP3310384A1 (en) | 2015-06-17 | 2018-04-25 | CureVac AG | Vaccine composition |
| US10221127B2 (en) | 2015-06-29 | 2019-03-05 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| EP4516312A3 (en) | 2015-07-07 | 2025-04-30 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
| WO2017021546A1 (en) | 2015-08-05 | 2017-02-09 | Curevac Ag | Epidermal mrna vaccine |
| WO2017025120A1 (en) | 2015-08-07 | 2017-02-16 | Curevac Ag | Process for the in vivo production of rna in a host cell |
| CA2992801A1 (en) | 2015-08-28 | 2017-03-09 | Curevac Ag | Artificial nucleic acid molecules |
| WO2017048770A1 (en) | 2015-09-15 | 2017-03-23 | Regulus Therapeutics, Inc. | Systems, compositions, and methods for formulating nucleic acid compositions |
| SMT202200178T1 (it) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Composti e composizioni per il rilascio intracellulare di agenti terapeutici |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2017081082A2 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Optimized nucleic acid molecules |
| US11413346B2 (en) | 2015-11-09 | 2022-08-16 | Curevac Ag | Rotavirus vaccines |
| WO2017117528A1 (en) | 2015-12-30 | 2017-07-06 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| MX2018009917A (es) | 2016-02-17 | 2019-08-14 | Curevac Ag | Vacuna contra el virus del zika. |
| WO2017173054A1 (en) | 2016-03-30 | 2017-10-05 | Intellia Therapeutics, Inc. | Lipid nanoparticle formulations for crispr/cas components |
| EP3777881A1 (en) | 2016-04-22 | 2021-02-17 | CureVac AG | Rna encoding a tumor antigen |
| US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| AU2017350488B2 (en) | 2016-10-26 | 2022-06-23 | Acuitas Therapeutics Inc. | Lipid nanoparticle mRNA vaccines |
| WO2018081638A1 (en) | 2016-10-27 | 2018-05-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| US12065396B2 (en) | 2017-08-17 | 2024-08-20 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| AU2020205717B2 (en) | 2019-01-11 | 2025-09-11 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
-
2016
- 2016-04-27 CA CA2984125A patent/CA2984125A1/en active Pending
- 2016-04-27 US US15/569,546 patent/US20180303925A1/en not_active Abandoned
- 2016-04-27 JP JP2017556248A patent/JP2018526321A/ja active Pending
- 2016-04-27 AU AU2016253972A patent/AU2016253972B2/en active Active
- 2016-04-27 WO PCT/US2016/029572 patent/WO2016176330A1/en not_active Ceased
- 2016-04-27 EP EP16787068.2A patent/EP3289083A4/en active Pending
-
2020
- 2020-04-01 AU AU2020202322A patent/AU2020202322A1/en not_active Abandoned
-
2021
- 2021-06-08 JP JP2021096084A patent/JP7506030B2/ja active Active
- 2021-07-09 US US17/371,261 patent/US20220040285A1/en not_active Abandoned
-
2022
- 2022-03-28 US US17/705,837 patent/US12138305B2/en active Active
- 2022-11-04 AU AU2022263594A patent/AU2022263594B2/en active Active
-
2024
- 2024-04-03 JP JP2024060190A patent/JP2024084804A/ja active Pending
- 2024-10-24 US US18/925,561 patent/US20250064914A1/en active Pending
-
2025
- 2025-10-15 AU AU2025252537A patent/AU2025252537A1/en active Pending